ATE322894T1 - Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten - Google Patents

Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten

Info

Publication number
ATE322894T1
ATE322894T1 AT02716434T AT02716434T ATE322894T1 AT E322894 T1 ATE322894 T1 AT E322894T1 AT 02716434 T AT02716434 T AT 02716434T AT 02716434 T AT02716434 T AT 02716434T AT E322894 T1 ATE322894 T1 AT E322894T1
Authority
AT
Austria
Prior art keywords
carbostyril derivatives
subtype agonists
substituted carbostyril
ht1a subtype
ht1a
Prior art date
Application number
AT02716434T
Other languages
English (en)
Inventor
Shaun Jordan
Tetsuro Kikuchi
Katsura Tottori
Tsuyoshi Hirose
Yasufumi Uwahodo
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25087808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE322894(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of ATE322894T1 publication Critical patent/ATE322894T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02716434T 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten ATE322894T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77021001A 2001-01-29 2001-01-29

Publications (1)

Publication Number Publication Date
ATE322894T1 true ATE322894T1 (de) 2006-04-15

Family

ID=25087808

Family Applications (3)

Application Number Title Priority Date Filing Date
AT06015782T ATE504293T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung
AT05023971T ATE362763T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten
AT02716434T ATE322894T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT06015782T ATE504293T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung
AT05023971T ATE362763T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten

Country Status (19)

Country Link
EP (3) EP1355639B1 (de)
JP (4) JP4178032B2 (de)
KR (5) KR100825705B1 (de)
CN (3) CN1239154C (de)
AR (4) AR032641A1 (de)
AT (3) ATE504293T1 (de)
AU (4) AU2002226752C1 (de)
BR (1) BR0206237A (de)
CA (2) CA2700314C (de)
CY (3) CY1105631T1 (de)
DE (3) DE60220325T2 (de)
DK (3) DK1712225T3 (de)
ES (3) ES2286755T3 (de)
MX (2) MX344556B (de)
MY (1) MY129355A (de)
PH (1) PH12014500937A1 (de)
PT (3) PT1712225E (de)
TW (2) TWI302832B (de)
WO (1) WO2002060423A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
EP1551393A4 (de) * 2002-07-30 2010-06-16 Peter Migaly Kombinationstherapie gegen depression, prävention von suizid und verschiedener medizinischer und psychiatrischer erkrankungen
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
WO2004060374A1 (en) * 2002-12-27 2004-07-22 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
ZA200508306B (en) * 2003-05-23 2007-03-28 Otsuka Pharma Co Ltd Carbostyril derivatives and mood stabilizers for treating mood disorders
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
CA2617546C (en) * 2005-08-03 2014-07-15 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
TW200848041A (en) 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2009286740A (ja) * 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
EP2338873A1 (de) 2009-12-22 2011-06-29 Gmeiner, Peter Neue Aminotetralinderivate
TW201343201A (zh) 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd 持續釋放型口服固體製劑
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
US4764416A (en) 1986-07-01 1988-08-16 Mitsubishi Denki Kabushiki Kaisha Electric element circuit using oxidation-reduction substances
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3155276B2 (ja) * 1991-05-20 2001-04-09 ファルマシア・アンド・アップジョン・カンパニー カルボキサミド−(1,2n)−カルボサイクリック−2−アミノテトラリン誘導体
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
WO1994009765A1 (en) * 1992-10-23 1994-05-11 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
TR199802241T2 (de) * 1996-05-07 1999-02-22 Pfizer Inc.
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
KR20000035880A (ko) * 1996-08-27 2000-06-26 이곤 이 버그 도파민 d2 효능제 및 5ht1a 리간드로서의 4-아미노에톡시 인돌
WO1999038864A1 (en) * 1998-02-03 1999-08-05 American Home Products Corporation Oxazole derivatives as serotonin-1a receptor agonists
ZA992670B (en) * 1998-04-13 2000-10-12 American Home Prod 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists.
JPH11335286A (ja) * 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US20040204469A1 (en) * 2001-06-19 2004-10-14 Norbert Muller Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Also Published As

Publication number Publication date
AR080849A2 (es) 2012-05-09
EP1355639B1 (de) 2006-04-12
TWI302832B (en) 2008-11-11
KR20030065570A (ko) 2003-08-06
DE60220325T2 (de) 2008-01-17
JP5683010B2 (ja) 2015-03-11
DK1621198T3 (da) 2007-09-24
WO2002060423A2 (en) 2002-08-08
PT1621198E (pt) 2007-06-08
AR099754A2 (es) 2016-08-17
EP1621198A2 (de) 2006-02-01
AU2005201772B2 (en) 2007-05-17
ATE504293T1 (de) 2011-04-15
EP1621198B1 (de) 2007-05-23
CN1484524A (zh) 2004-03-24
EP1712225B1 (de) 2011-04-06
EP1712225A1 (de) 2006-10-18
JP4896831B2 (ja) 2012-03-14
JP2011225587A (ja) 2011-11-10
KR100713607B1 (ko) 2007-05-02
DE60210581T2 (de) 2007-04-05
JP2011184460A (ja) 2011-09-22
CA2429496C (en) 2010-10-19
EP1621198A3 (de) 2006-04-12
MXPA03006603A (es) 2004-02-12
CA2700314C (en) 2012-04-24
DE60239711D1 (de) 2011-05-19
AU2002226752B2 (en) 2005-03-17
DK1712225T3 (da) 2011-06-20
KR100653591B1 (ko) 2006-12-05
ES2363366T3 (es) 2011-08-02
CA2700314A1 (en) 2002-08-08
PT1355639E (pt) 2006-06-30
CN1879624A (zh) 2006-12-20
AR032641A1 (es) 2003-11-19
CY1108031T1 (el) 2013-09-04
MY129355A (en) 2007-03-30
AU2007201701B2 (en) 2010-06-17
ES2261652T3 (es) 2006-11-16
EP1355639A2 (de) 2003-10-29
KR100601073B1 (ko) 2006-07-19
CY1111392T1 (el) 2015-08-05
WO2002060423A3 (en) 2003-04-10
JP2007297405A (ja) 2007-11-15
AU2002226752C1 (en) 2010-02-18
AU2007201701A1 (en) 2007-05-10
KR20050107822A (ko) 2005-11-15
PH12014500937A1 (en) 2015-09-21
CN1239154C (zh) 2006-02-01
CY1105631T1 (el) 2010-12-22
DK1355639T3 (da) 2006-08-14
DE60220325D1 (de) 2007-07-05
KR100825705B1 (ko) 2008-04-29
CA2429496A1 (en) 2002-08-08
KR20060028485A (ko) 2006-03-29
AU2005201772A1 (en) 2005-05-19
AU2005201772C1 (en) 2010-06-03
HK1061805A1 (en) 2004-10-08
ES2286755T3 (es) 2007-12-01
JP2004517937A (ja) 2004-06-17
BR0206237A (pt) 2003-12-23
KR20070065425A (ko) 2007-06-22
JP4178032B2 (ja) 2008-11-12
DE60210581D1 (en) 2006-05-24
HK1091403A1 (zh) 2007-01-19
TW200522960A (en) 2005-07-16
CN1813745A (zh) 2006-08-09
KR20060085260A (ko) 2006-07-26
AR079761A2 (es) 2012-02-15
AU2009233591B2 (en) 2011-10-20
TWI331919B (en) 2010-10-21
CN100450485C (zh) 2009-01-14
KR100763288B1 (ko) 2007-10-04
AU2009233591A1 (en) 2009-11-19
PT1712225E (pt) 2011-04-18
MX344556B (es) 2016-12-20
ATE362763T1 (de) 2007-06-15

Similar Documents

Publication Publication Date Title
DE60220325D1 (de) Substituierte Carbostyrilderivate als 5-HT1A-Subtyp Agonisten
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
ATE392897T1 (de) Chinolinderivate als npy antagonisten
DE60317365D1 (de) Substituierte 4-alkoxyoxazol derivate als ppar agonisten
ATE414067T1 (de) Guanidinobenzamide als mc4-r agonisten
IS8439A (is) Nýjar kínólín afleiður
ATE370120T1 (de) Substituierte 2-pyridin-cyclohexan-1,4- diaminderivate
DE60308850D1 (de) Pyridinoylpiperidine als 5-ht1f agonisten
NO20041235L (no) Kinolinderivater som neuropeptid Y antagonister
DK1427709T3 (da) 3-substituerede 4-pyrimidonderivater
DE60226775D1 (de) Azaindolylalkylaminderivate als 5-hydroxytryptamin-6-liganden
NO20034970D0 (no) Nye arylheteroalkylaminderivater
DE60203529D1 (de) Indolderivate als cox-ii-inhibitoren
ATE413879T1 (de) ß(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)- ETHYLAMINO)- PROPYLPHENYL-DERIVATE ALS BETA2 AGONISTEN
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer
ATE308325T1 (de) Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trion derivate als metalloproteinase inhibitoren
ATE395333T1 (de) 4-phenylpiperazinyl, -piperidinyl und - tetrahydropyridyl-derivate als dopamin d4- antagonisten
ATE281435T1 (de) Phenyl-heterocyclyl-ether-derivate als serotonin re-uptake inhibitoren
ATE309994T1 (de) Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
ATE410428T1 (de) Pyrroloä2,1-cüä1,4übenzodiazepine als vasopressin-agonisten
DE60214138D1 (de) Isoxazolin-derivate als antidepressiva
DE60201463D1 (de) Indanon-Derivate als Duftstoffe
DE60210058D1 (de) Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
DE60129445D1 (de) Quinolin-derivate als antientzündungsmittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1355639

Country of ref document: EP